Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme Article Swipe
Marjan Van Blerk
,
Els Bailleul
,
Bernard Châtelain
,
Anne Demulder
,
Katrien Devreese
,
Jonathan Douxfils
,
Marc Jacquemin
,
Kristin Jochmans
,
François Mullier
,
William Wijns
,
Bernard China
,
Kris Vernelen
,
Mohamed Rida Soumali
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1111/ijlh.12640
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.1111/ijlh.12640
Summary Introduction The Belgian national External Quality Assessment Scheme performed a survey to assess the effect of the direct oral anticoagulant apixaban on the coagulation assays prothrombin time ( PT ), activated partial thromboplastin time ( aPTT ), fibrinogen and antithrombin as performed with a large number of reagent/instrument combinations. Methods Four lyophilized plasma samples spiked with apixaban (0, 41, 94 and 225 ng/mL) were sent to the 195 Belgian and Luxembourg clinical laboratories performing coagulation testing. Results PT and aPTT were barely influenced at the concentrations tested. At 225 ng/mL apixaban, PT and aPTT clotting times were only 1.15 times longer than at 0 ng/mL. Among PT reagents, RecombiPlasTin 2G ® showed a slightly higher sensitivity with 225 ng/mL apixaban prolonging the PT clotting time 1.3‐fold. Among aPTT reagents, there was no appreciable difference in sensitivity. Fibrinogen results were unaffected by the presence of apixaban, but antithrombin activity was considerably overestimated when measured with a FX a‐based assay. At 225 ng/mL apixaban, the median percentage increase in antithrombin level was 31% when measured with the Liquid Antithrombin ® reagent and 44% with the Innovance Antithrombin ® reagent. Conclusion Our data provide clinical laboratories with useful information on the impact of apixaban on their routine coagulation assays.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1111/ijlh.12640
- OA Status
- green
- Cited By
- 26
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2581456358
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2581456358Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/ijlh.12640Digital Object Identifier
- Title
-
Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment SchemeWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2017Year of publication
- Publication date
-
2017-03-17Full publication date if available
- Authors
-
Marjan Van Blerk, Els Bailleul, Bernard Châtelain, Anne Demulder, Katrien Devreese, Jonathan Douxfils, Marc Jacquemin, Kristin Jochmans, François Mullier, William Wijns, Bernard China, Kris Vernelen, Mohamed Rida SoumaliList of authors in order
- Landing page
-
https://doi.org/10.1111/ijlh.12640Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://biblio.ugent.be/publication/8612464Direct OA link when available
- Concepts
-
Apixaban, Antithrombin, Partial thromboplastin time, Prothrombin time, Fibrinogen, Coagulation, External quality assessment, Clotting time, Chemistry, Coagulation testing, Thrombin time, Medicine, Chromatography, Internal medicine, Heparin, Biochemistry, Rivaroxaban, Pathology, Warfarin, Atrial fibrillationTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
26Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 3, 2023: 3, 2022: 3, 2021: 2Per-year citation counts (last 5 years)
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2581456358 |
|---|---|
| doi | https://doi.org/10.1111/ijlh.12640 |
| ids.doi | https://doi.org/10.1111/ijlh.12640 |
| ids.mag | 2581456358 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/28304137 |
| ids.openalex | https://openalex.org/W2581456358 |
| fwci | 3.01913587 |
| mesh[0].qualifier_ui | Q000097 |
| mesh[0].descriptor_ui | D000991 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | blood |
| mesh[0].descriptor_name | Antithrombins |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D001530 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Belgium |
| mesh[2].qualifier_ui | Q000187 |
| mesh[2].descriptor_ui | D001777 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | drug effects |
| mesh[2].descriptor_name | Blood Coagulation |
| mesh[3].qualifier_ui | Q000379 |
| mesh[3].descriptor_ui | D001780 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | methods |
| mesh[3].descriptor_name | Blood Coagulation Tests |
| mesh[4].qualifier_ui | Q000592 |
| mesh[4].descriptor_ui | D001780 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | standards |
| mesh[4].descriptor_name | Blood Coagulation Tests |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D016903 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Drug Monitoring |
| mesh[6].qualifier_ui | Q000494 |
| mesh[6].descriptor_ui | D065427 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | pharmacology |
| mesh[6].descriptor_name | Factor Xa Inhibitors |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D065427 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Factor Xa Inhibitors |
| mesh[8].qualifier_ui | Q000096 |
| mesh[8].descriptor_ui | D005340 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | biosynthesis |
| mesh[8].descriptor_name | Fibrinogen |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D006801 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Humans |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D010314 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Partial Thromboplastin Time |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D011517 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Prothrombin Time |
| mesh[12].qualifier_ui | Q000494 |
| mesh[12].descriptor_ui | D011720 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | pharmacology |
| mesh[12].descriptor_name | Pyrazoles |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D011720 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Pyrazoles |
| mesh[14].qualifier_ui | Q000494 |
| mesh[14].descriptor_ui | D011728 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | pharmacology |
| mesh[14].descriptor_name | Pyridones |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D011728 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Pyridones |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D011785 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Quality Assurance, Health Care |
| mesh[17].qualifier_ui | Q000097 |
| mesh[17].descriptor_ui | D000991 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | blood |
| mesh[17].descriptor_name | Antithrombins |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D001530 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Belgium |
| mesh[19].qualifier_ui | Q000187 |
| mesh[19].descriptor_ui | D001777 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | drug effects |
| mesh[19].descriptor_name | Blood Coagulation |
| mesh[20].qualifier_ui | Q000379 |
| mesh[20].descriptor_ui | D001780 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | methods |
| mesh[20].descriptor_name | Blood Coagulation Tests |
| mesh[21].qualifier_ui | Q000592 |
| mesh[21].descriptor_ui | D001780 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | standards |
| mesh[21].descriptor_name | Blood Coagulation Tests |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D016903 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Drug Monitoring |
| mesh[23].qualifier_ui | Q000494 |
| mesh[23].descriptor_ui | D065427 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | pharmacology |
| mesh[23].descriptor_name | Factor Xa Inhibitors |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D065427 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Factor Xa Inhibitors |
| mesh[25].qualifier_ui | Q000096 |
| mesh[25].descriptor_ui | D005340 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | biosynthesis |
| mesh[25].descriptor_name | Fibrinogen |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D006801 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Humans |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D010314 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Partial Thromboplastin Time |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D011517 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Prothrombin Time |
| mesh[29].qualifier_ui | Q000494 |
| mesh[29].descriptor_ui | D011720 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | pharmacology |
| mesh[29].descriptor_name | Pyrazoles |
| mesh[30].qualifier_ui | Q000627 |
| mesh[30].descriptor_ui | D011720 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | therapeutic use |
| mesh[30].descriptor_name | Pyrazoles |
| mesh[31].qualifier_ui | Q000494 |
| mesh[31].descriptor_ui | D011728 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | pharmacology |
| mesh[31].descriptor_name | Pyridones |
| mesh[32].qualifier_ui | Q000627 |
| mesh[32].descriptor_ui | D011728 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | therapeutic use |
| mesh[32].descriptor_name | Pyridones |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D011785 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Quality Assurance, Health Care |
| type | article |
| title | Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme |
| biblio.issue | 4 |
| biblio.volume | 39 |
| biblio.last_page | 408 |
| biblio.first_page | 402 |
| topics[0].id | https://openalex.org/T10065 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2705 |
| topics[0].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[0].display_name | Atrial Fibrillation Management and Outcomes |
| topics[1].id | https://openalex.org/T10292 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9970999956130981 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Acute Myocardial Infarction Research |
| topics[2].id | https://openalex.org/T12352 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.995199978351593 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Heparin-Induced Thrombocytopenia and Thrombosis |
| is_xpac | False |
| apc_list.value | 3550 |
| apc_list.currency | USD |
| apc_list.value_usd | 3550 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780638905 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9218227863311768 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q414462 |
| concepts[0].display_name | Apixaban |
| concepts[1].id | https://openalex.org/C2779026020 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8011872172355652 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q416336 |
| concepts[1].display_name | Antithrombin |
| concepts[2].id | https://openalex.org/C2778261982 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7116395831108093 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1755136 |
| concepts[2].display_name | Partial thromboplastin time |
| concepts[3].id | https://openalex.org/C2780434524 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6655929088592529 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1144385 |
| concepts[3].display_name | Prothrombin time |
| concepts[4].id | https://openalex.org/C2779036427 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6419072151184082 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q381899 |
| concepts[4].display_name | Fibrinogen |
| concepts[5].id | https://openalex.org/C2778382381 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6236737370491028 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q179217 |
| concepts[5].display_name | Coagulation |
| concepts[6].id | https://openalex.org/C2778618615 |
| concepts[6].level | 2 |
| concepts[6].score | 0.6229495406150818 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q4008393 |
| concepts[6].display_name | External quality assessment |
| concepts[7].id | https://openalex.org/C77171857 |
| concepts[7].level | 3 |
| concepts[7].score | 0.578126072883606 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q5135593 |
| concepts[7].display_name | Clotting time |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.5778969526290894 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| concepts[9].id | https://openalex.org/C16124881 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4838241934776306 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q5363933 |
| concepts[9].display_name | Coagulation testing |
| concepts[10].id | https://openalex.org/C2780077467 |
| concepts[10].level | 4 |
| concepts[10].score | 0.4305686354637146 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2520736 |
| concepts[10].display_name | Thrombin time |
| concepts[11].id | https://openalex.org/C71924100 |
| concepts[11].level | 0 |
| concepts[11].score | 0.3721751570701599 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[11].display_name | Medicine |
| concepts[12].id | https://openalex.org/C43617362 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3647320568561554 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[12].display_name | Chromatography |
| concepts[13].id | https://openalex.org/C126322002 |
| concepts[13].level | 1 |
| concepts[13].score | 0.25586897134780884 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[13].display_name | Internal medicine |
| concepts[14].id | https://openalex.org/C2777557582 |
| concepts[14].level | 2 |
| concepts[14].score | 0.19756916165351868 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q190016 |
| concepts[14].display_name | Heparin |
| concepts[15].id | https://openalex.org/C55493867 |
| concepts[15].level | 1 |
| concepts[15].score | 0.1289566457271576 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[15].display_name | Biochemistry |
| concepts[16].id | https://openalex.org/C2778661090 |
| concepts[16].level | 4 |
| concepts[16].score | 0.1282234787940979 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q420262 |
| concepts[16].display_name | Rivaroxaban |
| concepts[17].id | https://openalex.org/C142724271 |
| concepts[17].level | 1 |
| concepts[17].score | 0.055323272943496704 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[17].display_name | Pathology |
| concepts[18].id | https://openalex.org/C2776301958 |
| concepts[18].level | 3 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q407431 |
| concepts[18].display_name | Warfarin |
| concepts[19].id | https://openalex.org/C2779161974 |
| concepts[19].level | 2 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q815819 |
| concepts[19].display_name | Atrial fibrillation |
| keywords[0].id | https://openalex.org/keywords/apixaban |
| keywords[0].score | 0.9218227863311768 |
| keywords[0].display_name | Apixaban |
| keywords[1].id | https://openalex.org/keywords/antithrombin |
| keywords[1].score | 0.8011872172355652 |
| keywords[1].display_name | Antithrombin |
| keywords[2].id | https://openalex.org/keywords/partial-thromboplastin-time |
| keywords[2].score | 0.7116395831108093 |
| keywords[2].display_name | Partial thromboplastin time |
| keywords[3].id | https://openalex.org/keywords/prothrombin-time |
| keywords[3].score | 0.6655929088592529 |
| keywords[3].display_name | Prothrombin time |
| keywords[4].id | https://openalex.org/keywords/fibrinogen |
| keywords[4].score | 0.6419072151184082 |
| keywords[4].display_name | Fibrinogen |
| keywords[5].id | https://openalex.org/keywords/coagulation |
| keywords[5].score | 0.6236737370491028 |
| keywords[5].display_name | Coagulation |
| keywords[6].id | https://openalex.org/keywords/external-quality-assessment |
| keywords[6].score | 0.6229495406150818 |
| keywords[6].display_name | External quality assessment |
| keywords[7].id | https://openalex.org/keywords/clotting-time |
| keywords[7].score | 0.578126072883606 |
| keywords[7].display_name | Clotting time |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.5778969526290894 |
| keywords[8].display_name | Chemistry |
| keywords[9].id | https://openalex.org/keywords/coagulation-testing |
| keywords[9].score | 0.4838241934776306 |
| keywords[9].display_name | Coagulation testing |
| keywords[10].id | https://openalex.org/keywords/thrombin-time |
| keywords[10].score | 0.4305686354637146 |
| keywords[10].display_name | Thrombin time |
| keywords[11].id | https://openalex.org/keywords/medicine |
| keywords[11].score | 0.3721751570701599 |
| keywords[11].display_name | Medicine |
| keywords[12].id | https://openalex.org/keywords/chromatography |
| keywords[12].score | 0.3647320568561554 |
| keywords[12].display_name | Chromatography |
| keywords[13].id | https://openalex.org/keywords/internal-medicine |
| keywords[13].score | 0.25586897134780884 |
| keywords[13].display_name | Internal medicine |
| keywords[14].id | https://openalex.org/keywords/heparin |
| keywords[14].score | 0.19756916165351868 |
| keywords[14].display_name | Heparin |
| keywords[15].id | https://openalex.org/keywords/biochemistry |
| keywords[15].score | 0.1289566457271576 |
| keywords[15].display_name | Biochemistry |
| keywords[16].id | https://openalex.org/keywords/rivaroxaban |
| keywords[16].score | 0.1282234787940979 |
| keywords[16].display_name | Rivaroxaban |
| keywords[17].id | https://openalex.org/keywords/pathology |
| keywords[17].score | 0.055323272943496704 |
| keywords[17].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.1111/ijlh.12640 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S66208518 |
| locations[0].source.issn | 1751-5521, 1751-553X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1751-5521 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | International Journal of Laboratory Hematology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | International Journal of Laboratory Hematology |
| locations[0].landing_page_url | https://doi.org/10.1111/ijlh.12640 |
| locations[1].id | pmid:28304137 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | International journal of laboratory hematology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/28304137 |
| locations[2].id | pmh:oai:archive.ugent.be:8612464 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400477 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Ghent University Academic Bibliography (Ghent University) |
| locations[2].source.host_organization | https://openalex.org/I32597200 |
| locations[2].source.host_organization_name | Ghent University |
| locations[2].source.host_organization_lineage | https://openalex.org/I32597200 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | publishedVersion |
| locations[2].raw_type | journalArticle |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | True |
| locations[2].is_published | True |
| locations[2].raw_source_name | International Journal of Laboratory Hematology |
| locations[2].landing_page_url | https://biblio.ugent.be/publication/8612464 |
| locations[3].id | pmh:oai:archive.ugent.be:8504183 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306400477 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Ghent University Academic Bibliography (Ghent University) |
| locations[3].source.host_organization | https://openalex.org/I32597200 |
| locations[3].source.host_organization_name | Ghent University |
| locations[3].source.host_organization_lineage | https://openalex.org/I32597200 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | journalArticle |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY |
| locations[3].landing_page_url | http://hdl.handle.net/1854/LU-8504183 |
| locations[4].id | pmh:oai:vubissmart:VUBISSMART:2000:139202 |
| locations[4].is_oa | False |
| locations[4].source.id | https://openalex.org/S4306402573 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | VUBIR (Vrije Universiteit Brussel) |
| locations[4].source.host_organization | https://openalex.org/I13469542 |
| locations[4].source.host_organization_name | Vrije Universiteit Brussel |
| locations[4].source.host_organization_lineage | https://openalex.org/I13469542 |
| locations[4].license | |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | article |
| locations[4].license_id | |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | |
| locations[4].landing_page_url | https://biblio.vub.ac.be/vubir/(350c5406-53ff-442c-a206-77b8f04aae21).html |
| locations[5].id | pmh:oai:dial.uclouvain.be:boreal:183720 |
| locations[5].is_oa | False |
| locations[5].source.id | https://openalex.org/S4306400166 |
| locations[5].source.issn | |
| locations[5].source.type | repository |
| locations[5].source.is_oa | False |
| locations[5].source.issn_l | |
| locations[5].source.is_core | False |
| locations[5].source.is_in_doaj | False |
| locations[5].source.display_name | Digital Access to Libraries |
| locations[5].source.host_organization | https://openalex.org/I2800384882 |
| locations[5].source.host_organization_name | Harris County Public Library |
| locations[5].source.host_organization_lineage | https://openalex.org/I2800384882 |
| locations[5].license | |
| locations[5].pdf_url | |
| locations[5].version | submittedVersion |
| locations[5].raw_type | info:eu-repo/semantics/article |
| locations[5].license_id | |
| locations[5].is_accepted | False |
| locations[5].is_published | False |
| locations[5].raw_source_name | International Journal of Laboratory Hematology, Vol. 39, no. 4, p. 402-408 (2017) |
| locations[5].landing_page_url | http://hdl.handle.net/2078.1/183720 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5020990615 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2238-3773 |
| authorships[0].author.display_name | Marjan Van Blerk |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210158280 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I4210158280 |
| authorships[0].institutions[0].ror | https://ror.org/04ws26165 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210158280 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | Institut Scientifique de Santé Publique |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | M. Van Blerk |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[1].author.id | https://openalex.org/A5090844623 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Els Bailleul |
| authorships[1].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | E. Bailleul |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[2].author.id | https://openalex.org/A5109892826 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Bernard Châtelain |
| authorships[2].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | B. Chatelain |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[3].author.id | https://openalex.org/A5018368376 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5198-8536 |
| authorships[3].author.display_name | Anne Demulder |
| authorships[3].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | A. Demulder |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[4].author.id | https://openalex.org/A5071705224 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7559-2579 |
| authorships[4].author.display_name | Katrien Devreese |
| authorships[4].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | K. Devreese |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[5].author.id | https://openalex.org/A5078686392 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-7644-5298 |
| authorships[5].author.display_name | Jonathan Douxfils |
| authorships[5].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | J. Douxfils |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[6].author.id | https://openalex.org/A5066776334 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-4780-268X |
| authorships[6].author.display_name | Marc Jacquemin |
| authorships[6].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | M. Jacquemin |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[7].author.id | https://openalex.org/A5013999329 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-7819-8091 |
| authorships[7].author.display_name | Kristin Jochmans |
| authorships[7].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | K. Jochmans |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[8].author.id | https://openalex.org/A5000944048 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-6947-6099 |
| authorships[8].author.display_name | François Mullier |
| authorships[8].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | F. Mullier |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[9].author.id | https://openalex.org/A5033359462 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-7267-4376 |
| authorships[9].author.display_name | William Wijns |
| authorships[9].affiliations[0].raw_affiliation_string | EQA Advisory Board, Brussels, Belgium |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | W. Wijns |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | EQA Advisory Board, Brussels, Belgium |
| authorships[10].author.id | https://openalex.org/A5064310362 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-5717-478X |
| authorships[10].author.display_name | Bernard China |
| authorships[10].countries | BE |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210158280 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[10].institutions[0].id | https://openalex.org/I4210158280 |
| authorships[10].institutions[0].ror | https://ror.org/04ws26165 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210158280 |
| authorships[10].institutions[0].country_code | BE |
| authorships[10].institutions[0].display_name | Institut Scientifique de Santé Publique |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | B. China |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[11].author.id | https://openalex.org/A5052103341 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Kris Vernelen |
| authorships[11].countries | BE |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210158280 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[11].institutions[0].id | https://openalex.org/I4210158280 |
| authorships[11].institutions[0].ror | https://ror.org/04ws26165 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210158280 |
| authorships[11].institutions[0].country_code | BE |
| authorships[11].institutions[0].display_name | Institut Scientifique de Santé Publique |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | K. Vernelen |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[12].author.id | https://openalex.org/A5003450766 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-5213-0227 |
| authorships[12].author.display_name | Mohamed Rida Soumali |
| authorships[12].countries | BE |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210158280 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| authorships[12].institutions[0].id | https://openalex.org/I4210158280 |
| authorships[12].institutions[0].ror | https://ror.org/04ws26165 |
| authorships[12].institutions[0].type | facility |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210158280 |
| authorships[12].institutions[0].country_code | BE |
| authorships[12].institutions[0].display_name | Institut Scientifique de Santé Publique |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | M. R. Soumali |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://biblio.ugent.be/publication/8612464 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10065 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2705 |
| primary_topic.subfield.display_name | Cardiology and Cardiovascular Medicine |
| primary_topic.display_name | Atrial Fibrillation Management and Outcomes |
| related_works | https://openalex.org/W2351323014, https://openalex.org/W4285367771, https://openalex.org/W3031692095, https://openalex.org/W2360293419, https://openalex.org/W2379432586, https://openalex.org/W2022430958, https://openalex.org/W2141141994, https://openalex.org/W2357452117, https://openalex.org/W2010203179, https://openalex.org/W2581456358 |
| cited_by_count | 26 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 3 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 2 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 5 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 4 |
| counts_by_year[7].year | 2018 |
| counts_by_year[7].cited_by_count | 3 |
| counts_by_year[8].year | 2017 |
| counts_by_year[8].cited_by_count | 2 |
| locations_count | 6 |
| best_oa_location.id | pmh:oai:archive.ugent.be:8612464 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306400477 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Ghent University Academic Bibliography (Ghent University) |
| best_oa_location.source.host_organization | https://openalex.org/I32597200 |
| best_oa_location.source.host_organization_name | Ghent University |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I32597200 |
| best_oa_location.license | other-oa |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journalArticle |
| best_oa_location.license_id | https://openalex.org/licenses/other-oa |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | International Journal of Laboratory Hematology |
| best_oa_location.landing_page_url | https://biblio.ugent.be/publication/8612464 |
| primary_location.id | doi:10.1111/ijlh.12640 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S66208518 |
| primary_location.source.issn | 1751-5521, 1751-553X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1751-5521 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | International Journal of Laboratory Hematology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | International Journal of Laboratory Hematology |
| primary_location.landing_page_url | https://doi.org/10.1111/ijlh.12640 |
| publication_date | 2017-03-17 |
| publication_year | 2017 |
| referenced_works | https://openalex.org/W2158014557, https://openalex.org/W2085073510, https://openalex.org/W1754932965, https://openalex.org/W2071156500, https://openalex.org/W2103196751, https://openalex.org/W2073510057, https://openalex.org/W2029696469, https://openalex.org/W2170260432, https://openalex.org/W2322354498, https://openalex.org/W1884576739, https://openalex.org/W2010099904, https://openalex.org/W2040812969, https://openalex.org/W1967894356, https://openalex.org/W2055958936, https://openalex.org/W2126507631, https://openalex.org/W2316036320, https://openalex.org/W2412757059, https://openalex.org/W2520740086, https://openalex.org/W2198244152, https://openalex.org/W2511296650, https://openalex.org/W2198635349, https://openalex.org/W2023363122 |
| referenced_works_count | 22 |
| abstract_inverted_index.( | 28, 35 |
| abstract_inverted_index.0 | 104 |
| abstract_inverted_index.a | 10, 44, 113, 155 |
| abstract_inverted_index.), | 30, 37 |
| abstract_inverted_index.2G | 110 |
| abstract_inverted_index.94 | 60 |
| abstract_inverted_index.At | 88, 159 |
| abstract_inverted_index.FX | 156 |
| abstract_inverted_index.PT | 29, 78, 92, 107, 123 |
| abstract_inverted_index.as | 41 |
| abstract_inverted_index.at | 84, 103 |
| abstract_inverted_index.by | 141 |
| abstract_inverted_index.in | 135, 167 |
| abstract_inverted_index.no | 132 |
| abstract_inverted_index.of | 16, 47, 144, 200 |
| abstract_inverted_index.on | 22, 197, 202 |
| abstract_inverted_index.to | 12, 66 |
| abstract_inverted_index.® | 111, 178, 186 |
| abstract_inverted_index.(0, | 58 |
| abstract_inverted_index.195 | 68 |
| abstract_inverted_index.225 | 62, 89, 118, 160 |
| abstract_inverted_index.31% | 171 |
| abstract_inverted_index.41, | 59 |
| abstract_inverted_index.44% | 181 |
| abstract_inverted_index.Our | 189 |
| abstract_inverted_index.The | 2 |
| abstract_inverted_index.and | 39, 61, 70, 79, 93, 180 |
| abstract_inverted_index.but | 146 |
| abstract_inverted_index.the | 14, 17, 23, 67, 85, 122, 142, 163, 175, 183, 198 |
| abstract_inverted_index.was | 131, 149, 170 |
| abstract_inverted_index.1.15 | 99 |
| abstract_inverted_index.Four | 51 |
| abstract_inverted_index.aPTT | 36, 80, 94, 128 |
| abstract_inverted_index.data | 190 |
| abstract_inverted_index.only | 98 |
| abstract_inverted_index.oral | 19 |
| abstract_inverted_index.sent | 65 |
| abstract_inverted_index.than | 102 |
| abstract_inverted_index.time | 27, 34, 125 |
| abstract_inverted_index.were | 64, 81, 97, 139 |
| abstract_inverted_index.when | 152, 172 |
| abstract_inverted_index.with | 43, 56, 117, 154, 174, 182, 194 |
| abstract_inverted_index.Among | 106, 127 |
| abstract_inverted_index.large | 45 |
| abstract_inverted_index.level | 169 |
| abstract_inverted_index.ng/mL | 90, 119, 161 |
| abstract_inverted_index.their | 203 |
| abstract_inverted_index.there | 130 |
| abstract_inverted_index.times | 96, 100 |
| abstract_inverted_index.Liquid | 176 |
| abstract_inverted_index.Scheme | 8 |
| abstract_inverted_index.assay. | 158 |
| abstract_inverted_index.assays | 25 |
| abstract_inverted_index.assess | 13 |
| abstract_inverted_index.barely | 82 |
| abstract_inverted_index.direct | 18 |
| abstract_inverted_index.effect | 15 |
| abstract_inverted_index.higher | 115 |
| abstract_inverted_index.impact | 199 |
| abstract_inverted_index.longer | 101 |
| abstract_inverted_index.median | 164 |
| abstract_inverted_index.ng/mL) | 63 |
| abstract_inverted_index.ng/mL. | 105 |
| abstract_inverted_index.number | 46 |
| abstract_inverted_index.plasma | 53 |
| abstract_inverted_index.showed | 112 |
| abstract_inverted_index.spiked | 55 |
| abstract_inverted_index.survey | 11 |
| abstract_inverted_index.useful | 195 |
| abstract_inverted_index.Belgian | 3, 69 |
| abstract_inverted_index.Methods | 50 |
| abstract_inverted_index.Quality | 6 |
| abstract_inverted_index.Results | 77 |
| abstract_inverted_index.Summary | 0 |
| abstract_inverted_index.assays. | 206 |
| abstract_inverted_index.partial | 32 |
| abstract_inverted_index.provide | 191 |
| abstract_inverted_index.reagent | 179 |
| abstract_inverted_index.results | 138 |
| abstract_inverted_index.routine | 204 |
| abstract_inverted_index.samples | 54 |
| abstract_inverted_index.tested. | 87 |
| abstract_inverted_index.External | 5 |
| abstract_inverted_index.activity | 148 |
| abstract_inverted_index.apixaban | 21, 57, 120, 201 |
| abstract_inverted_index.clinical | 72, 192 |
| abstract_inverted_index.clotting | 95, 124 |
| abstract_inverted_index.increase | 166 |
| abstract_inverted_index.measured | 153, 173 |
| abstract_inverted_index.national | 4 |
| abstract_inverted_index.presence | 143 |
| abstract_inverted_index.reagent. | 187 |
| abstract_inverted_index.slightly | 114 |
| abstract_inverted_index.testing. | 76 |
| abstract_inverted_index.Innovance | 184 |
| abstract_inverted_index.activated | 31 |
| abstract_inverted_index.apixaban, | 91, 145, 162 |
| abstract_inverted_index.a‐based | 157 |
| abstract_inverted_index.performed | 9, 42 |
| abstract_inverted_index.reagents, | 108, 129 |
| abstract_inverted_index.Assessment | 7 |
| abstract_inverted_index.Conclusion | 188 |
| abstract_inverted_index.Fibrinogen | 137 |
| abstract_inverted_index.Luxembourg | 71 |
| abstract_inverted_index.difference | 134 |
| abstract_inverted_index.fibrinogen | 38 |
| abstract_inverted_index.influenced | 83 |
| abstract_inverted_index.percentage | 165 |
| abstract_inverted_index.performing | 74 |
| abstract_inverted_index.prolonging | 121 |
| abstract_inverted_index.unaffected | 140 |
| abstract_inverted_index.1.3‐fold. | 126 |
| abstract_inverted_index.appreciable | 133 |
| abstract_inverted_index.coagulation | 24, 75, 205 |
| abstract_inverted_index.information | 196 |
| abstract_inverted_index.lyophilized | 52 |
| abstract_inverted_index.prothrombin | 26 |
| abstract_inverted_index.sensitivity | 116 |
| abstract_inverted_index.Antithrombin | 177, 185 |
| abstract_inverted_index.Introduction | 1 |
| abstract_inverted_index.antithrombin | 40, 147, 168 |
| abstract_inverted_index.considerably | 150 |
| abstract_inverted_index.laboratories | 73, 193 |
| abstract_inverted_index.sensitivity. | 136 |
| abstract_inverted_index.anticoagulant | 20 |
| abstract_inverted_index.combinations. | 49 |
| abstract_inverted_index.overestimated | 151 |
| abstract_inverted_index.RecombiPlasTin | 109 |
| abstract_inverted_index.concentrations | 86 |
| abstract_inverted_index.thromboplastin | 33 |
| abstract_inverted_index.reagent/instrument | 48 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5020990615 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 13 |
| corresponding_institution_ids | https://openalex.org/I4210158280 |
| citation_normalized_percentile.value | 0.90242548 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |